Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phentolamine/pilocarpine - Opus Genetics

Next Previous
Drug Profile

Phentolamine/pilocarpine - Opus Genetics

Alternative Names: 0.75% Nyxol + Low-Dose 0.4% Pilocarpine Eye Drops; 1%Nyxol+miotic; FDC-P; Miotic/phentolamine; Nyxol + Low-Dose Pilocarpine Eye Drops; Phentolamine/miotic; Pilocarpine/phentolamine

Latest Information Update: 24 Oct 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ocuphire Pharma
  • Developer Opus Genetics
  • Class Alkaloids; Aniline compounds; Antiglaucomas; Erectile dysfunction therapies; Eye disorder therapies; Furans; Imidazoles; Miotics; Peripheral vasodilators; Phenols; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor antagonists; Alpha 2 adrenergic receptor antagonists; Muscarinic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Presbyopia

Most Recent Events

  • 22 Oct 2024 Ocuphire Pharma has merged with Opus Genetics to form Opus Genetics
  • 10 Jan 2023 Phase-III clinical trials in Presbyopia in USA (Ophthalmic) (NCT05646719)
  • 09 Jan 2023 Occuphire Pharma plans a phase III VEGA 3 trial for Presbyopia in 2023 (Opthalmic)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top